Literature DB >> 9428926

Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer.

H Tsujimoto1, H Sugihara, A Hagiwara, T Hattori.   

Abstract

To study the background of oncogene amplification in gastric cancers, we examined the correlation between occurrence of oncogene amplification and DNA ploidy pattern. In 57 primary gastric cancers, amplifications of c-erbB, c-erbB-2, c-met and K-sam genes were investigated by Southern blot analysis, and the DNA ploidy pattern was determined by static cytofluorometry and by flow cytometry. Oncogene amplification was detected in 11 cancers, 10 of which were advanced gastric cancers and 1 was an early differentiated type. The amplification of c-erbB-2 and K-sam genes was found exclusively in differentiated- and undifferentiated-type cancers, respectively. Of the 11 cancers, 5 were DNA-diploid and 6 were DNA-aneuploid. All the 11 tumours with oncogene amplification contained polyploid cell populations (polyploidy), whereas none of the tumours without polyploidy showed oncogene amplification. In differentiated-type cancers the incidence of polyploidy was high in both early and advanced stages, while in undifferentiated-type cancers it was low in early stages but significantly higher in advanced stages. It was shown that amplification of growth factor receptor genes is closely related to the presence of polyploidy, irrespective of any different stemline DNA-ploidy mode. The time-course of oncogene amplification and kinds of genes amplified may differ between differentiated- and undifferentiated-type gastric cancers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9428926     DOI: 10.1007/s004280050115

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  20 in total

1.  Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase.

Authors:  M Kobayashi; S Nagata; T Iwasaki; K Yanagihara; I Saitoh; Y Karouji; S Ihara; Y Fukui
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR.

Authors:  Ghasem Janbabai; Ziaeddin Oladi; Touraj Farazmandfar; Tarang Taghvaei; Farshad Naghshvar
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-29       Impact factor: 4.553

3.  Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.

Authors:  Yu Kataoka; Toru Mukohara; Hideo Tomioka; Yohei Funakoshi; Naomi Kiyota; Yutaka Fujiwara; Masakazu Yashiro; Kosei Hirakawa; Midori Hirai; Hironobu Minami
Journal:  Invest New Drugs       Date:  2011-06-08       Impact factor: 3.850

4.  siRNA-participated chemotherapy: an efficient and specific therapeutic against gastric cancer.

Authors:  Donglei Zhou; Xun Jiang; Weixing Ding; Lijun Zheng; Lei Yang; Chengzhu Zheng; Liesheng Lu
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-28       Impact factor: 4.553

5.  RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Authors:  Daniel V T Catenacci; Gustavo Cervantes; Soheil Yala; Erik A Nelson; Essam El-Hashani; Rajani Kanteti; Mohamed El Dinali; Rifat Hasina; Johannes Brägelmann; Tanguy Seiwert; Michele Sanicola; Les Henderson; Tatyana A Grushko; Olufunmilayo Olopade; Theodore Karrison; Yung-Jue Bang; Woo Ho Kim; Maria Tretiakova; Everett Vokes; David A Frank; Hedy L Kindler; Heather Huet; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2011-07-01       Impact factor: 4.742

6.  MET expression and amplification in patients with localized gastric cancer.

Authors:  Yelena Y Janjigian; Laura H Tang; Daniel G Coit; David P Kelsen; Todd D Francone; Martin R Weiser; Suresh C Jhanwar; Manish A Shah
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-03-10       Impact factor: 4.254

7.  MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.

Authors:  F Cappuzzo; P A Jänne; M Skokan; G Finocchiaro; E Rossi; C Ligorio; P A Zucali; L Terracciano; L Toschi; M Roncalli; A Destro; M Incarbone; M Alloisio; A Santoro; M Varella-Garcia
Journal:  Ann Oncol       Date:  2008-10-03       Impact factor: 32.976

8.  Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.

Authors:  Brittny N Tillman; Megan Yanik; Andrew C Birkeland; Chia-Jen Liu; Daniel H Hovelson; Andi K Cani; Nallasivam Palanisamy; Shannon Carskadon; Thomas E Carey; Carol R Bradford; Scott A Tomlins; Jonathan B McHugh; Matthew E Spector; J Chad Brenner
Journal:  Head Neck       Date:  2016-02-05       Impact factor: 3.147

9.  MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome.

Authors:  H E Lee; M A Kim; H S Lee; E-J Jung; H-K Yang; B L Lee; Y-J Bang; W H Kim
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

10.  Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models.

Authors:  Paul R Gavine; Yongxin Ren; Lu Han; Jing Lv; Shiming Fan; Wei Zhang; Wen Xu; Yuan Jie Liu; Tianwei Zhang; Haihua Fu; Yongjuan Yu; Huiying Wang; Shirlian Xu; Feng Zhou; Xinying Su; XiaoLu Yin; Liang Xie; Linfang Wang; Weiguo Qing; Longxian Jiao; Weiguo Su; Q May Wang
Journal:  Mol Oncol       Date:  2014-09-10       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.